Mark Nestor, MD
Dermatology · Aventura, FLNPI 1063417665
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Ipsen Innovation at 45.8% of the total. Reporting peaked in 2020 at $231,873 and has fallen 58.8% since, to $95,475 in 2025. Among dermatology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $4745.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Innovation$259K
- Sensus Healthcare, Inc.$180K
- Ipsen Pharma SAS$30K
- Galderma Laboratories, L.p.$24K
- Regeneron$19K
- Ipsen Biopharm Limited$17K
- plus $36K from 18 others
Across 57 payments — averaging $20,518 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merz North America, Inc.$451K
- Sun Pharmaceutical Industries Inc.$338K
- Biofrontera Inc.$254K
- Aclaris Therapeutics, Inc.$112K
- Incyte Corporation$6K
- VYNE Pharmaceuticals Inc.$4K
- plus $3K from 2 others
What the payments were for
- Consulting fees$229,24741%
- Speaking & faculty fees$302,29054%
- Travel & lodging$17,8853%
- Food & beverage$10,7412%
- Education$4,5811%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Innovation | 26 | $258,596 |
| Sensus Healthcare, Inc. | 13 | $180,123 |
| Ipsen Pharma SAS | 4 | $30,009 |
| Galderma Laboratories, L.p. | 8 | $23,586 |
| Regeneron | 16 | $19,178 |
| Ipsen Biopharm Limited | 2 | $16,853 |
| Sun Pharmaceutical Industries Inc. | 6 | $15,243 |
| AbbVie(2 entities) | 13 | $5,906 |
| Biofrontera Inc. | 3 | $4,150 |
| Dermira, Inc. | 5 | $3,156 |
| Strata Skin Sciences, Inc. | 1 | $2,500 |
| Almirall LLC | 2 | $2,306 |
| Botanix SB Inc | 1 | $2,200 |
| Revance Therapeutics, Inc. | 9 | $268 |
| Incyte Corporation | 1 | $156 |
| Verrica Pharmaceuticals Inc. | 1 | $124 |
| E.r. Squibb & Sons, L.L.C. | 1 | $114 |
| Pfizer | 1 | $76 |
| Aclaris Therapeutics, Inc. | 1 | $61 |
| UCB, Inc. | 1 | $47 |
| Encore Dermatology Inc. | 1 | $41 |
| Sanofi | 1 | $23 |
| Biotissue Holdings Inc. | 1 | $17 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$564,744 in reported general payments places this provider in the 95th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpzeluraRuxolitinib Phosphate | 17 | $34,013 |
| Azelaic Acid | 40 | $5,358 |
| Ketoconazole | 210 | $3,049 |
| Mometasone Furoate | 68 | $1,488 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 52 | $1,459 |
| Mupirocin | 145 | $1,072 |
| Betamethasone Dipropionate | 30 | $1,019 |
| Fluocinolone Acetonide | 24 | $651 |
| Doxycycline Hyclate | 38 | $602 |
| Ciclopirox | 24 | $426 |
| Triamcinolone Acetonide | 37 | $414 |
| ValacyclovirValacyclovir Hcl | 23 | $410 |
| Hydrocortisone | 32 | $141 |
| Minoxidil | 14 | $135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationOpzelura | $156 | $34,01317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,147 dermatology providers in Florida.
Other dermatology in Aventura
- Brian BermanAventura$405K
- Barry ResnikAventura$182K
- Francisco KerdelMiami$2.1M
- Brad GlickMargate$2M
- Robert KirsnerMiami$1.4M
- John MinniStuart$1.4M
- Gil YosipovitchMiami$1M
- Shino Bay AguileraFt Lauderdale$1M
- Robert SnyderPembroke Pines$1M
- Marc IngleseTallahassee$989K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.